This brand name is authorized in Spain, Lithuania, Poland
The drug VIDPREVTYN BETA contains one active pharmaceutical ingredient (API):
|
1
UNII E68GYP6X53 - SARS-COV2 501.V2 VARIANT
|
|
|
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| VIDPREVTYN BETA Solution and emulsion for emulsion for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J07BN02 | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BN Covid-19 vaccines | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 1211580001 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1095933 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
